These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 8514651)
1. Liposomal hamycin in the control of experimental aspergillosis in mice: effect of phosphatidic acid with and without cholesterol. Moonis M; Ahmad I; Bachhawat BK J Antimicrob Chemother; 1993 Apr; 31(4):569-79. PubMed ID: 8514651 [TBL] [Abstract][Full Text] [Related]
2. Mannosylated liposomes as carriers for hamycin in the treatment of experimental aspergillosis in Balb/C mice. Moonis M; Ahmad I; Bachhawat BK J Drug Target; 1993; 1(2):147-55. PubMed ID: 8069553 [TBL] [Abstract][Full Text] [Related]
3. Liposomal hamycin in the control of experimental aspergillosis in mice: relative toxicity, therapeutic efficacy and tissue distribution of free and liposomal hamycin. Moonis M; Ahmad I; Bachhawat BK Indian J Biochem Biophys; 1992 Aug; 29(4):339-45. PubMed ID: 1427960 [TBL] [Abstract][Full Text] [Related]
4. Liposomal hamycin: reduced toxicity and improved antifungal efficacy in vitro and in vivo. Mehta RT; McQueen TJ; Keyhani A; Lopez-Berestein G J Infect Dis; 1991 Nov; 164(5):1003-6. PubMed ID: 1940451 [TBL] [Abstract][Full Text] [Related]
5. Liposomal amphotericin-B in the control of experimental aspergillosis in mice: Part I--Relative therapeutic efficacy of free and liposomal amphotericin-B. Ahmad I; Sarkar AK; Bachhawat BK Indian J Biochem Biophys; 1989 Dec; 26(6):351-6. PubMed ID: 2698855 [TBL] [Abstract][Full Text] [Related]
6. Mannose-coated liposomal hamycin in the treatment of experimental leishmaniasis in hamsters. Banerjee G; Bhaduri AN; Basu MK Biochem Med Metab Biol; 1994 Oct; 53(1):1-7. PubMed ID: 7857676 [TBL] [Abstract][Full Text] [Related]
7. Design of liposomes to improve delivery of amphotericin-B in the treatment of aspergillosis. Ahmad I; Sarkar AK; Bachhawat BK Mol Cell Biochem; 1989 Nov 23-Dec 19; 91(1-2):85-90. PubMed ID: 2695834 [TBL] [Abstract][Full Text] [Related]
8. Effect of cholesterol in various liposomal compositions on the in vivo toxicity, therapeutic efficacy, and tissue distribution of amphotericin B. Ahmad I; Sarkar AK; Bachhawat BK Biotechnol Appl Biochem; 1990 Oct; 12(5):550-6. PubMed ID: 2288711 [TBL] [Abstract][Full Text] [Related]
9. Tissue distribution and antifungal effect of liposomal itraconazole in experimental cryptococcosis and pulmonary aspergillosis. Le Conte P; Joly V; Saint-Julien L; Gillardin JM; Carbon C; Yeni P Am Rev Respir Dis; 1992 Feb; 145(2 Pt 1):424-9. PubMed ID: 1310577 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy. Schwendener RA; Fiebig HH; Berger MR; Berger DP Cancer Chemother Pharmacol; 1991; 27(6):429-39. PubMed ID: 2013113 [TBL] [Abstract][Full Text] [Related]
11. Aerosolised liposomal hamycin for treatment of systemic Candida infections in mice. Dhuley JN FEMS Immunol Med Microbiol; 1999 Aug; 25(3):231-6. PubMed ID: 10459577 [TBL] [Abstract][Full Text] [Related]
12. Chemotherapeutic activity of liposomal SJA-95: a new polyene macrolide antibiotic in experimental aspergillosis and cryptococcosis. Desai SK; Naik SR Biomed Pharmacother; 2009 May; 63(4):287-92. PubMed ID: 18848764 [TBL] [Abstract][Full Text] [Related]
13. Neoglycoprotein conjugated liposomes as macrophage specific drug carrier in the therapy of leishmaniasis. Kole L; Sakar K; Mahato SB; Das PK Biochem Biophys Res Commun; 1994 Apr; 200(1):351-8. PubMed ID: 8166705 [TBL] [Abstract][Full Text] [Related]
14. Liposomal amphotericin-B as a therapeutic measure to control experimental aspergillosis in BALB/c mice. Ahmad I; Sarkar AK; Bachhawat BK Indian J Biochem Biophys; 1990 Dec; 27(6):370-4. PubMed ID: 2102483 [No Abstract] [Full Text] [Related]
15. Effect of elimination of phagocytic cells by liposomal dichloromethylene diphosphonate on aspergillosis virulence and toxicity of liposomal amphotericin B in mice. Moonis M; Ahmad I; Bachhawat BK J Antimicrob Chemother; 1994 Mar; 33(3):571-83. PubMed ID: 8040121 [TBL] [Abstract][Full Text] [Related]
16. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Mayer LD; Tai LC; Ko DS; Masin D; Ginsberg RS; Cullis PR; Bally MB Cancer Res; 1989 Nov; 49(21):5922-30. PubMed ID: 2790807 [TBL] [Abstract][Full Text] [Related]
17. Liposomal entrapment of the neutrophil-derived peptide indolicidin endows it with in vivo antifungal activity. Ahmad I; Perkins WR; Lupan DM; Selsted ME; Janoff AS Biochim Biophys Acta; 1995 Jul; 1237(2):109-14. PubMed ID: 7632702 [TBL] [Abstract][Full Text] [Related]
18. Preparation, relative toxicity and therapeutic efficacy in mice and rats of liposomal HA-1-92, a new oxohexaene polyene macrolide antibiotic. Harindran J; Chakraborty KK; Naik SR J Pharm Pharmacol; 1999 Jul; 51(7):771-6. PubMed ID: 10467950 [TBL] [Abstract][Full Text] [Related]
19. Safety, efficacy and pharmacokinetics of tuftsin-loaded nystatin liposomes in murine model. Khan MA; Faisal SM; Mohammad O J Drug Target; 2006 May; 14(4):233-41. PubMed ID: 16777682 [TBL] [Abstract][Full Text] [Related]
20. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Lewis RE; Liao G; Hou J; Chamilos G; Prince RA; Kontoyiannis DP Antimicrob Agents Chemother; 2007 Apr; 51(4):1253-8. PubMed ID: 17261624 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]